Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03829410 · ClinicalTrials.gov registry record · Phase 1
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
A Phase 1 study, sponsored by Cardiff Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03829410 is a Phase 1 study that has completed, run by Cardiff Oncology. The registered enrollment target is 68 participants.
The verdict
NCT03829410, a Phase 1 study, has completed, sponsored by Cardiff Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a KRAS mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab.
Interventions
- BIOLOGICAL Bevacizumab
- DRUG FOLFIRI
- DRUG Onvansertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03829410
The ClinicalTrials.gov registry entry for NCT03829410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiff Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT03829410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03829410 about?
NCT03829410 is a clinical study titled "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation". The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a...
What is the current status of trial NCT03829410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2019-06-24. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT03829410?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), FOLFIRI (DRUG), Onvansertib (DRUG).
Who is sponsoring clinical trial NCT03829410?
This trial is sponsored by Cardiff Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.